Inozyme Pharma, Inc.
INZY · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $21 | $35 | $33 | $23 |
| Short-Term Investments | $92 | $154 | $95 | $88 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | -$0 | -$0 |
| Other Curr. Assets | $7 | $7 | $3 | $3 |
| Total Curr. Assets | $121 | $196 | $131 | $115 |
| Property Plant & Equip (Net) | $1 | $3 | $4 | $4 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $1 | $2 | $4 | $3 |
| Total NC Assets | $3 | $5 | $8 | $8 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $123 | $201 | $139 | $124 |
| Liabilities | – | – | – | – |
| Payables | $3 | $1 | $3 | $2 |
| Short-Term Debt | $15 | $1 | $2 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $4 | $0 |
| Other Curr. Liab. | $16 | $13 | $11 | $8 |
| Total Curr. Liab. | $34 | $15 | $15 | $12 |
| LT Debt | $31 | $46 | $6 | $3 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $31 | $46 | $6 | $3 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $1 | $2 | $3 | $3 |
| Total Liabilities | $65 | $60 | $21 | $14 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$388 | -$286 | -$215 | -$148 |
| AOCI | $0 | $0 | -$0 | $0 |
| Other Equity | $446 | $426 | $333 | $257 |
| Total Equity | $58 | $140 | $119 | $109 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $123 | $201 | $139 | $124 |
| Net Debt | $26 | $12 | -$25 | -$19 |